Navigation Links
Enox Biopharma, Inc. Expands Its Technology to Cover the Wound Care Market
Date:5/31/2011

VANCOUVER, British Columbia, May 31, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has expanded its technology to cover the wound care market by filing a patent application on novel means of delivering nitric oxide directly to wounds.

Nitric oxide is well recognized as both an antimicrobial agent which can prevent infections and as a vasodilator which can accelerate wound healing. The unstable nature of nitric oxide has, until now, prevented its clinical use. Enox Biopharma has already protected the dosing of polymers with nitric oxide which is sequestered in the polymer in a stable state. The nitric oxide remains in the polymer until it is used clinically at which point it emits nitric oxide over the period of weeks. Our new technology allows us to deliver nitric oxide directly to wounds which may prevent infections while expediting the healing process ultimately facilitating the closing of chronic wounds that would not otherwise heal.

"The inability to heal foot ulcers in the diabetic patient leads to over one million leg amputations per year according to the World Diabetes Foundation," noted Enox's founder and President Professor Yossef Av-Gay. "It is conceivable that we could replace this gruesome standard of care with a noninvasive nitric oxide delivery method. It will take time and clinical research to determine if this is indeed possible but the potential is certainly there."

John Rewcastle, Ph.D., Chief Executive Officer of Enox, commented, "The wound care market is drastically underserved today. Although we can't yet fully disclose the details of our patent application, we believe the novel delivery method, which we are in the process of fully protecting globally will meet the need of millions of patients worldwide. We are excited to contribute to the wound care market which is expected to exceed twenty billion dollars by 2015."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide. Enox's wound healing NO delivery technology could lead to revolutionary changes in chronic wound care standards of care.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
2. Enox Biopharma, Inc. Appoints Dr. John Rewcastle as CEO
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
5. BioStorage Technologies Expands U.S. Operations with Opening of New Biorepository Facility
6. DATATRAK Academy Expands to Include Durham Technical Community College
7. Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
8. Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director
9. Online Career Service for Postgraduate Life Scientists Expands Membership to Individuals
10. GeneWize Expands DNA Customization into 3 Mega Markets
11. China-Biotics Expands Product Supplied to Bright Dairy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):